Research Statement
My research focuses on the pathophysiological role of receptor-mediated prorenin/renin's actions in renal fibrosis and the non-viral strategies for cell-specific delivery of pathway-interactors and molecular probles to diseased kidneys.
Education History
Postdoctoral Fellowship |
University of Utah School of Medicine |
Postdoctoral Fellow |
---|---|---|
Fudan University Shanghai Medical College |
PhD | |
Fellowship |
Shanghai Medical College, Fudan University |
Fellow |
Zhenjiang Medical College Hospital, Jiangsu University |
Resident | |
Internship |
Zhenjiang Medical College |
Intern |
Zhenjiang Medical College, Jiangsu University |
MD |
Selected Publications
Journal Article
- Tian M, Carroll LS, Tang L, Uehara H, Westenfelder C, Ambati BK, and Huang Y (2020). Systemic AAV10.COMP-Ang1 rescues renal glomeruli and pancreatic islets in type 2 diabetic mice. BMJ Open Diabetes Res Care, 8(1), e000882.
- Liu S, Huang Z, Tang A, Wu X, Aube J, Xu L, Xing C and Huang Y (2020). Inhibition of RNA-binding protein HuR reduces glomerulosclerosis in experimental nephritis. Clin Sci (Lond), 134, 1433-1448.
- Zhang Y, Hansson KM, Liu T, Magnell K, Huang Y, Carlson NG, Kishore BK (2018). Genetic Deletion of ADP-activated P2Y12 Receptor Ameliorates Lithium-induced Nephrogenic Diabetes Insipidus in Mice. Acta Physiol (Oxf), 225, e13191.
- Conlin CC, Huang Y, Gordon BAJ, Zhang JL (2018). Quantitative characterization of glomerular fibrosis with magnetic resonance imaging. A feasibility study in a rat glomerulonephritis model. 314, F747-F752.
- Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, Geschwindner S, Aagaard A, Granqvist AB, Jaisser F, Huang Y, Granberg KL, Jansson-Lofmark R, Hartleib-Geschwindner J (2018). Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One, 13(2), E0193380.
- Zhou G, Wu J, Gu C, Wang B, Abel ED, Cheung AK, and Huang Y (2018). Prorenin independently causes hypertension and renal and cardiac fibrosis in cyp1a1 prorenin transgenic rats. Clin Sci (Lond), 132, 1345-1363.
- Tian M, Tang L, Wu Y, Beddhu S, Huang Y (2018). Adiponectin attenuates kidney injury and fibrosis in Deoxycorticosterone Acetate-Salt and Angiotensin II-induced CKD mice.
- Conlin CC, Oesingmann N, Bolster Jr B Huang Y, Lee VS, and Zhang JL (2016). Renal plasma flow (RPF) measured with multiple-inversion-time arterial spin labeling (ASL) and tracer kinetic analysis: Validation against a dynamic contrast enhancement method. Magn Reson Imaging, 37, 51-55.
- Tang L, Wu Y, Tian M, Sjostrom CD, Johansson U, Peng XR, Smith DM and Huang Y (2017). Dapagliflozin slows the progression of the renal and liver fiboriss associated with type 2 diabetes. Am J Physiol Endocrinol Metab, 313(5), E563-E576.
- Hwang J, Huang Y, Burwell TJ, Peterson NC, Connor J, Weiss SJ, Yu SM, Li Y (2017). In situ imaging of tissue remodeling with collagen hybridizing peptides. ACS Nano, 11, 9825-9835.
- Klein J, Ramirez-Torres A, Ericsson A, Huang Y, Breuil B, Siwy J, Mischak H, Peng XR, Bascands JL, Schanstra JP (2016). Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney Int, 90, 1045-1055.
- Gu C, Zhang J, Noble NA, Peng XR, Huang Y (2016). An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease. 311, F852- F863.
- Zhou G, Johansson U, Peng XR, Bamberg K, Huang Y (03/15/2016). An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am J Transl Res, 8(3), 1339-54.
- Beddhu S, Filipowicz R, Wang B, Wei G, Cheng X, Roy AC, Duvall S, Farrukh H, Habib A, Bjhordahl T, Simmons D, Munger M, Stoddard G, Kohan D, Greene T and Huang Y (2016). A randomized controlled trial of the effects of febuxostat therapy on adiokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Can J Kidney Health Dis, 3, 1-11.
- Conlin CC, Oesingmann N, Bolster Jr B, Huang Y, Lee VS, Zhang JL (2016). Renal plasma flow (RPF) measured with multiple-inversion-time arterial spin labeling (ASL) and tracer kinetic analysis: Validation against a dynamic contrast enhancement method. Magn Reson Imaging, (37), 51-55.
- Zhou G, Liu X, Cheung AK, Huang Y (2015). Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus? Am J Transl Res, 7(5), 825-40.
- Gu C, Noble NA, Border WA, Cheung AK and Huang Y (2014). Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocyte. J Renin Angiotensin Aldosterone Syst, 15, 177-189.
- Zhang J, Gu C, Lawrence DA, Cheung AK and Huang Y (2014). A PAI-1 mutant retards diabetic nephropathy in db/db mice through protecting podocytes. Exp Physiol, 99, 802-815.
- Guo X, Zhou G, Guo M, Cheung AK, Huang Y and Beddhu S (2014). Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II. Physiol Res, 2, e00230.
- Zhou G, Cheung AK, Liu X and Huang Y (2013). Valsartan slows the progression of diabetic nephropathy in db/db mice via reduction in podocyte injury and renal oxidative stress and inflammation. Clin Sci (Lond), 126, 707-720.
- Zhang J, Wu J, Gu C, Noble NA, Border WA and Huang Y (2012). Receptor-mediated non-proteolytic activation of prorenin and induction of TGFß1 and PAI-1 expression in renal mesangial cells. 303, F11-20.
- Zhang J, Gu C, Noble NA, Border WA and Huang Y (2011). Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. 301, F723-732.
- Zhang J, Noble NA, Border WA and Huang Y (2010). infusion of angiotensin-(1-7) reduces glomerulosclerosis in anti-thy 1 glomerulonephritis. 298, F579-588.
- Huang Y, Border WA, Lawrence DA, Noble NA (2009). Mechanisms underlying the anti-fibrotic properties of non-inhibitory PAI-1 (PAI-1R) in experimental nephritis. on line.
- Ge Y, Huang Y, Kohan DE (2008). Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure. Can J Physiol Pharmacol, 2008(86), 329-336.
- Zhang J, Noble NA, Border WA and Huang Y corresponding author (2008). Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. Am J Physiol Endocrinol Metab, 295, E810-E819.
- Huang Y, Border WA, Yu L, Zhang J, Lawrence DA and Noble NA (2008). A non-inhibitory PAI-1 retards the progression of diabetic nephropathy in db/db mice. J Am Soc Nephrol, 2008(86), 329-336.
- Huang W, Xu C, Kahng K, Noble NA, Border WA and Huang Y corresponding author (2008). Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. 2008(294), F1287-1295.
- Huang Y, Noble NA, Zhang J, Xu C, Border WA (2007). Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int, 72(1), 45-52.
- Huang Y, Border WA, Lawrence DA, Noble NA (2006). Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int, 70(3), 515.
- Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA and Border WA (2006). Renin increases mesangial cell transforming growth factor-ß1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int, 69(1), 105.
- Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA (2004). Combining TGFß inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int, 66, 1774.
- Li ZP, Xu X, Huang YF, Zhu JF, Wang XJ, Hu HH, He ZP (2003). Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor for occurrence of diabetic retinopathy (Chinese). Zhonghua Yan Ke Za Zhi, 39(6), 352-6.
- Huang Y, Haraguchi M, Lawrence DA, Border WA, Noble NA (2003). A mutant, non-inhibitory plasminogen activator inhibitor-type 1 (PAI-1) decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest, 112, 337-388.
- Yu L, Border WA, Huang Y, Noble NA (2003). TGFß isoforms and renal fibrogenesis. Kidney Int, 64, 844-856.
- Xu X, Li Z, Luo D, Huang Y, Zhu J, Wang X, Hu H, Patrick CP (2003). Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol, 241(1), 56-62.
- Haraguchi M, Border WA, Huang Y, Noble NA (2001). t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int, 59, 2146-2155.
- Huang Y, Shanyan L, Jianghua Z (1998). Gene expression of receptor for advanced glycation end products and its modulation by Aminoguanidine in diabetic kidney tissue. Chin Med J (Engl), 111 (8), 698.
Review
- Huang Y, Noble NA (2007). PAI-1 as a Target in Kidney Disease. [Review]. Curr Drug Targets, 8(9), 1007-15.
- Huang Y, Border WA, Noble NA (2007). Functional Renin Receptors in Renal Mesangial Cells. [Review]. Curr Hypertens Rep, 9(2), 133-139.
Editorial
- Huang Y, Border WA and Noble NA (2006). Perspectives on blockade of TGF-ß overexpression. Kidney Int, 69(10), 1713.
- Yufeng Huang, Nancy A Noble (2005). An unexpected role of plasminogen activator inhibitor-type 1 (PAI-1) in renal fibrosis. Kidney Int, 67, 2502.